Drucker Wealth 3.0 LLC Grows Position in Becton, Dickinson and Company (NYSE:BDX)

Drucker Wealth 3.0 LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 321.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,601 shares of the medical instruments supplier's stock after buying an additional 11,897 shares during the period. Drucker Wealth 3.0 LLC's holdings in Becton, Dickinson and Company were worth $3,539,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Brighton Jones LLC raised its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares during the last quarter. E. Ohman J or Asset Management AB increased its holdings in shares of Becton, Dickinson and Company by 13.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier's stock valued at $39,951,000 after purchasing an additional 20,859 shares during the period. Busey Bank raised its stake in shares of Becton, Dickinson and Company by 3.8% in the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier's stock worth $15,031,000 after purchasing an additional 2,399 shares during the last quarter. Swedbank AB raised its stake in shares of Becton, Dickinson and Company by 1.0% in the fourth quarter. Swedbank AB now owns 152,293 shares of the medical instruments supplier's stock worth $34,551,000 after purchasing an additional 1,455 shares during the last quarter. Finally, Phraction Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 7.2% during the fourth quarter. Phraction Management LLC now owns 47,021 shares of the medical instruments supplier's stock worth $10,668,000 after purchasing an additional 3,138 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 459 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $230.00, for a total value of $105,570.00. Following the sale, the executive vice president now owns 6,952 shares of the company's stock, valued at $1,598,960. The trade was a 6.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the transaction, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,878 shares of company stock worth $636,393. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Up 1.8%

Shares of NYSE BDX traded up $3.10 during trading on Tuesday, hitting $174.48. 2,010,580 shares of the company were exchanged, compared to its average volume of 1,932,323. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a fifty day moving average price of $197.15 and a 200-day moving average price of $218.17. The firm has a market capitalization of $50.01 billion, a PE ratio of 28.98, a P/E/G ratio of 1.63 and a beta of 0.31.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.35 billion. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Becton, Dickinson and Company's quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.17 earnings per share. As a group, equities research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has approved a stock buyback program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.

Analyst Ratings Changes

BDX has been the subject of a number of recent research reports. Wall Street Zen lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Morgan Stanley cut their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research report on Tuesday, May 6th. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $260.00 to $185.00 in a research report on Friday, May 2nd. Raymond James downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Finally, Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $221.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.